| Detailed information |
|---|
| CancerLivER ID | 2218 |
| Biomarker | MYC |
| Biomarker Name/Symbol (given in Publication) | MYC |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Diagnostic or therapeutic biomarkers associated with HCC and validated on independent dataset |
| Experimental Condition | HCV-associated HCC v/s healthy/non-tumor/cirrhosis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in HCC |
| Level of significance | p < 0.0001 |
| Source | Tissue |
| PMID | 28947976 |
| Type of Biomarker | Diagnostic |
| Pathway | ErbB, VEGF and MAPK signaling pathways |
| Cohort | GSE25097 dataset contain 557 samples, including 6 healthy livers, 40 cirrhotic tissue samples, 243 adjacent non-tumor samples, and 268 early-to-advanced stage HCC samples; GSE6764 dataset contains a total of 75 tissue samples, including 10 healthy liver samples, 13 cirrhosis samples, 17 dysplastic |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2017 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |